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Introduction Methods 
Conclusions 
We hypothesize that ESWL treatment will decrease NO and increase H2O2 release in 
rat renal veins compared to no-ESWL controls. We further hypothesize that a post-
ESWL i.v. bolus of PKCε+/BH4 will increase NO and decrease H2O2 release compared to 
ESWL + saline controls. Whereas, we expect a post-ESWL i.v. infusion of PKCε+/BH2 
will decrease NO and increase H2O2 compared to ESWL + saline controls. We 
hypothesize that PKCε- given with either BH4 or BH2 after ESWL will increase NO and 
decrease H2O2 release compared to ESWL + saline controls. 
ESWL treatment decreased NO and increased H2O2 blood levels compared to no-
ESWL controls. This supports our hypothesis and previous findings in this lab that 
ESWL causes oxidative stress and reduced NO bioavailability. Post-ESWL PKCε+/BH4 
significantly attenuated the adverse effects of ESWL by increasing NO and decreasing 
H2O2 release compared to ESWL+saline. This suggests that this combination enhances 
eNOS in its coupled state. Whereas, post-ESWL PKCε+/BH2 was similar to ESWL 
control in H2O2 and NO, suggesting that BH2 is nearing saturation to the eNOS binding 
site. In contrast, post-ESWL PKCε- with either BH4 or BH2 resulted in increased NO 
and decreased H2O2 compared to ESWL+saline. This suggests that PKCε- attenuates 
eNOS uncoupled activity after ESWL. Potentially, this study can help to develop 
therapeutic uses for PKCε+/BH4 or PKCε- in the attenuation of vascular endothelial 
dysfunction following ESWL treatment and possibly eliminate or reduce the acute 
renal complications that may lead to chronic conditions such as hypertension. 
Results 
Male Sprague-Dawley rats (275-325g, Charles River, Springfield, MA) were 
anesthetized with an induction dose of sodium pentobarbital (60 mg/kg) 
intraperitoneally. A maintenance dose (30 mg/kg) was administered at intervals of 45 
minutes unless otherwise required. The rat also received sodium heparin (1000 USP 
units/mL) i.p. to act as an anticoagulant. The rat’s left external jugular vein was 
exposed and catherized with a 24-gauge angio-catheter for drug or saline infusion 
post-ESWL treatment. The rat was then subjected to a mid-line laparotomy, and the 
left renal vein was isolated. A 22-gauge angio-catheter was inserted into the left renal 
vein in direct opposition of the blood flow. A NO or H2O2 microsensor was inserted 
into the renal vein catheter and connected to the TBR 4100 Free Radical Analyzer 
(World Precision Instruments, Inc., Sarasota, FL) which produces a trace showing real-
time measurements of NO or H2O2 release recorded in picoamps (pA). The 
microsensors receive an electrical signal proportional to the free radical 
concentration through an oxidation/reduction reaction. Baseline measurements 
were then taken until a stable baseline (i.e., 300 pA decrease per 300 seconds) was 
achieved. Thereafter, the baseline was set to a “zero” reading, and all measurements 
post-ESWL were expressed as relative change from baseline. Once a stable baseline 
was established, ESWL treatment was initiated by a Dornier Epos Ultra Lithotripter 
(1000 shocks, 500 at 60 beats/min, 500 at 120 beats/min, 16kV, 1.3mHz). To simulate 
conditions in the no-ESWL control group, the approximate time of treatment (13 
min) was maintained without ESWL treatment. Immediately following ESWL or at the 
same time for no-ESWL controls, 0.5 mL of saline or drug bolus was infused through 
the jugular vein canulation followed by a 0.5mL saline flush. Experimental groups 
included combinations of PKCε+ (N-Myr-HADPIGYD, 1097 g/mol, Genemed 
Synthesis) or PKCε- (N-Myr-EAVSLKPT, 1054 g/mol, Genemed Synthesis) with BH4 
(314 g/mol, Cayman Chemicals) or BH2 (239 g/mol, Cayman Chemicals). Recordings 
of NO and H2O2 release were taken throughout the experiment (baseline, ESWL end, 
30 min post-ESWL). The microsensors were calibrated prior to each experiment in 
order to create a standard calibration curve via a stepwise dose-response to the 
appropriate standard solution. NO readings in pA were converted to nanomoles/L 
(nM), and H2O2 readings in pA were converted to micromoles/L (µM). 
Figure 3. Effect of PKCε+ Combined with BH4 or BH2 on Real-Time Blood NO and H2O2 Release 
after ESWL. ESWL significantly decreased NO release and increased H2O2 release (5-30 mins 
post-ESWL) compared to no-ESWL controls. Administration of PKCε+/BH4 after ESWL was similar 
to no-ESWL controls, significantly increasing NO and decreasing H2O2release (5-30 mins post-
ESWL) compared to ESWL controls. Post-ESWL infusion of PKCε+/BH2 was similar to the ESWL 
control group in both NO and H2O2 release. (*p≤0.05, **p≤0.01, compared to ESWL controls) 
(#p≤0.05, ##p≤0.01, compared to ESWL with PKCε+/BH2) 
Figure 4. Effect of PKCε- Combined with BH4 or BH2 on Real-Time Blood NO and H2O2 Release 
after ESWL. Post-ESWL infusions of PKCε-/BH4 or PKCε-/BH2 are both similar to no-ESWL 
controls, significantly increasing NO release (5-30 mins) and decreasing H2O2 release (15-30 
mins) compared to ESWL controls. (*p≤0.05, **p≤0.01, compared to ESWL  controls) 
Figure 2. The rat was placed supine on a working board with the left kidney in the focal point of 
the lithotripter. The microsensor was supported by a catheter in the left renal vein, and the 
microsensor tip was positioned so that it was in direct contact with the renal vein blood flow. 
All data was presented as means ±SEM. The data for each time-point were 
compared by ANOVA using post-hoc analysis with the Student Newman Keuls test. 
Probability values of less than 0.05 were considered to be statistically significant. 
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Experimental Groups: 
Nitric Oxide (NO) 
1. No-ESWL with Saline (Control) (n=6) 
2. ESWL with Saline (Control) (n=5) 
3. ESWL with PKCε+/BH4 (n=5) 
 (0.9 mg/kg; 0.8 mg/kg) 
4. ESWL with PKCε+/BH2 (n=5) 
(0.9 mg/kg; 2 mg/kg) 
5. ESWL with PKCε-/BH4 (n=5) 
 (0.8 mg/kg; 0.8 mg/kg) 
6. ESWL with PKCε-/BH2 (n=5) 
 (0.8 mg/kg;  2 mg/kg) 
 
 
Hydrogen Peroxide (H2O2) 
7. No-ESWL with Saline (Control) (n=6) 
8. ESWL with Saline (Control) (n=6) 
9.  ESWL with PKCε+/BH4 (n=5) 
 (0.9 mg/kg; 0.8 mg/kg) 
10. ESWL with PKCε+/BH2 (n=5)  
 (0.9 mg/kg; 2 mg/kg) 
11. ESWL with PKCε-/BH4 (n=5) 
 (0.8 mg/kg; 0.8 mg/kg) 
12. ESWL with PKCε-/BH2 (n=5) 
 (0.8 mg/kg;  2 mg/kg) 
 
Coupled eNOS Uncoupled eNOS 
ESWL is a clinical therapy to break down kidney and uretal stones into smaller 
fragments that are more easily eliminated through the urinary tract. High-energy 
shock waves are focused on the stone to cause shear stress and cavitation bubbles 
which synergistically ablate the stones. While ESWL is the preferred treatment for 
kidney stones over invasive surgeries, the repetitive shock waves necessary to break 
up the stones may also cause damage to the renal vasculature endothelium and that 
can lead to chronic hypertension [1]. Previous studies have found that ESWL can 
cause endothelial dysfunction which is characterized decreased nitric oxide (NO) 
bioavailability and increased production of reactive oxygen species (ROS) such as 
superoxide (O2-) [2]. Normally, endothelial nitric oxide synthase (eNOS) is in a coupled 
state which forms NO in the presence of essential cofactor tetrahydrobiopterin (BH4) 
and molecular oxygen.  Oxidative stress, such as that caused by ESWL-induced ROS, 
can cause BH4 to be oxidized to dihydrobiopterin (BH2). When the BH2:BH4 ratio is 
increased, eNOS becomes uncoupled and produces O2- instead of NO [2, 3] (Figure 1). 
O2-  is short-lived and converted to hydrogen peroxide (H2O2) in blood by superoxide 
dismutase. Protein kinase C epsilon (PKCε) has previously been found to regulate 
eNOS activity via phosphorylation at serine-1177. Cell-permeable PKCε peptide 
activator (PKCε+) increases eNOS activity while PKCε inhibitor (PKCε-) reduces eNOS 
activity [2]. Using a combination of eNOS cofactors BH4 or BH2 with eNOS activity 
regulators PKCε+ or PKCε-, we can explore the role of modulating eNOS to reduce 
oxidative stress and endothelial dysfunction caused by ESWL. 
 
Figure 1. Coupled eNOS and Uncoupled eNOS. BH4 is the cofactor of coupled eNOS which 
results in NO production. ESWL-induced oxidative stress results in an increased BH2:BH4 ratio. 
BH2 is the cofactor for uncoupled eNOS which produces O2- and subsequently H2O2. 
Figure 2. Sources of ROS and the Role of PKCε. NADPH Oxidase releases O2- from leukocytes and 
endothelial cells. Mitochondria releases O2-  via incomplete oxidative phosphorylation. 
Uncoupled eNOS releases O2- in the presence of BH2. Increased O2-  quenches NO produced 
from coupled eNOS to produce ROS such as peroxynitrite (ONOO-) which reduces NO 
bioavailability and further increases oxidative stress. PKCε+ increases coupled and uncoupled 
eNOS activity, and PKCε- decreases coupled and uncoupled eNOS. 
